Index S&P 500 P/E 108.44 EPS (ttm) 1.07 Insider Own 1.26% Shs Outstand 174.88M Perf Week 0.48%
Market Cap 20.33B Forward P/E 32.51 EPS next Y 3.58 Insider Trans -1.42% Shs Float 172.82M Perf Month -8.96%
Income 184.07M PEG - EPS next Q 0.82 Inst Own 98.25% Short Float 2.46% Perf Quarter -6.52%
Sales 2.95B P/S 6.88 EPS this Y 533.62% Inst Trans -1.05% Short Ratio 4.16 Perf Half Y 26.36%
Book/sh 107.05 P/B 1.09 EPS next Y 4.49% ROA 0.49% Short Interest 4.26M Perf Year -2.88%
Cash/sh 4.18 P/C 27.78 EPS next 5Y -5.92% ROE 0.99% 52W Range 90.73 - 135.45 Perf YTD -8.31%
Dividend Est. 5.12 (4.41%) P/FCF 12.20 EPS past 5Y -31.25% ROI 0.59% 52W High -14.18% Beta 1.08
Dividend TTM 5.02 (4.32%) Quick Ratio - Sales past 5Y 16.91% Gross Margin 32.76% 52W Low 28.12% ATR (14) 3.37
Dividend Ex-Date Mar 27, 2024 Current Ratio - EPS Y/Y TTM -76.37% Oper. Margin 22.45% RSI (14) 39.34 Volatility 2.64% 2.40%
Employees 568 Debt/Eq 0.70 Sales Y/Y TTM 10.44% Profit Margin 6.23% Recom 1.15 Target Price 143.31
Option/Short Yes / Yes LT Debt/Eq 0.70 EPS Q/Q 120.29% Payout 916.99% Rel Volume 0.87 Prev Close 117.30
Sales Surprise -1.15% EPS Surprise 2.68% Sales Q/Q 9.75% Earnings Apr 22 AMC Avg Volume 1.02M Price 116.24
SMA20 -4.47% SMA50 -5.28% SMA200 0.16% Trades
Volume 888,218 Change -0.90%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-24 Initiated Deutsche Bank
Buy
$140
Oct-11-23 Initiated Exane BNP Paribas
Neutral
$108
Oct-03-23 Initiated Wedbush
Outperform
$120
Jul-20-23 Initiated Jefferies
Buy
$142
Jun-23-22 Initiated Credit Suisse
Neutral
$140
Jul-14-21 Resumed Mizuho
Buy
$200
Jan-07-21 Upgrade Robert W. Baird
Neutral → Outperform
$194
Oct-02-20 Initiated Berenberg
Buy
$190
Jun-08-20 Resumed JMP Securities
Mkt Outperform
$185
Feb-04-20 Resumed Mizuho
Buy
$190
Dec-18-19 Upgrade JP Morgan
Neutral → Overweight
$147 → $169
Dec-18-19 Downgrade RBC Capital Mkts
Top Pick → Outperform
$155 → $165
Dec-19-18 Upgrade JP Morgan
Underweight → Neutral
Dec-14-18 Upgrade RBC Capital Mkts
Outperform → Top Pick
Dec-03-18 Upgrade Citigroup
Neutral → Buy
Dec-04-17 Upgrade BofA/Merrill
Neutral → Buy
Aug-04-16 Reiterated RBC Capital Mkts
Outperform
$105 → $120
Aug-04-16 Reiterated Mizuho
Buy
$113 → $125
Jul-08-16 Reiterated Mizuho
Buy
$110 → $113
Oct-20-15 Reiterated Barclays
Overweight
$99 → $105
Show Previous Ratings
Apr-24-24 11:45AM
11:31AM
06:50AM
(Thomson Reuters StreetEvents)
03:13AM
Apr-23-24 02:31PM
09:32AM
Loading…
09:32AM
01:03AM
Apr-22-24 06:00PM
05:32PM
04:57PM
04:37PM
04:29PM
(Associated Press Finance)
04:10PM
Apr-18-24 05:42PM
09:50AM
11:42AM
Loading…
Apr-17-24 11:42AM
09:15AM
Apr-16-24 03:00AM
Apr-12-24 12:00PM
Apr-08-24 11:45AM
Apr-02-24 11:27AM
08:30AM
Apr-01-24 08:30AM
Mar-28-24 08:30AM
Mar-26-24 07:08AM
Mar-16-24 01:24AM
Mar-06-24 11:45AM
Mar-05-24 11:55AM
Mar-04-24 11:52PM
04:10PM
08:10AM
Loading…
08:10AM
07:00AM
Mar-01-24 08:00AM
Feb-28-24 11:24PM
08:30AM
Feb-27-24 07:00AM
Feb-20-24 05:58AM
Feb-19-24 11:45AM
Feb-12-24 11:29AM
08:30AM
Feb-01-24 06:42PM
11:45AM
09:22AM
08:50AM
Jan-31-24 06:30PM
05:45AM
(Thomson Reuters StreetEvents)
Jan-30-24 12:59PM
09:56AM
09:53AM
Jan-29-24 06:17PM
06:00PM
04:30PM
(Associated Press Finance)
04:10PM
Jan-26-24 08:30AM
Jan-25-24 09:56AM
Jan-24-24 09:15AM
Jan-17-24 03:55PM
Jan-16-24 03:30PM
Jan-10-24 09:30AM
Jan-09-24 05:25PM
10:54AM
Jan-05-24 09:55AM
08:30AM
Jan-03-24 06:35AM
Dec-27-23 08:50AM
Dec-19-23 10:01AM
Dec-18-23 04:04PM
Dec-17-23 04:44PM
Dec-16-23 03:00PM
Dec-15-23 10:51AM
09:53AM
08:30AM
Dec-14-23 08:30AM
Dec-07-23 03:35PM
03:06PM
Dec-05-23 10:44AM
Dec-04-23 04:10PM
08:30AM
Dec-01-23 10:05AM
Nov-30-23 08:30AM
Nov-29-23 10:28AM
Nov-28-23 09:15PM
08:00AM
Nov-22-23 09:09AM
Nov-12-23 08:45AM
Oct-29-23 05:28PM
Oct-26-23 07:40PM
Oct-25-23 12:28PM
07:30AM
(Thomson Reuters StreetEvents)
Oct-24-23 07:20AM
Oct-23-23 06:30PM
05:50PM
05:44PM
05:31PM
04:40PM
(Associated Press Finance)
04:10PM
Oct-20-23 12:00PM
Oct-19-23 08:30AM
Oct-17-23 10:57AM
Oct-11-23 08:30AM
Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. It offers properties for rent to life science, agriculture technology (agtech), and technology tenants. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lee Orraparn C. EVP - Accounting Mar 13 '24 Sale 126.67 3,000 380,010 43,146 Mar 15 04:31 PM Moglia Peter M Chief Executive Officer Mar 01 '24 Sale 122.90 3,200 393,280 249,683 Mar 04 06:25 PM MARCUS JOEL S Executive Chairman Feb 26 '24 Sale 118.92 7,500 891,900 429,538 Feb 28 04:31 PM Cain James P Director Dec 15 '23 Sale 131.05 660 86,493 5,620 Dec 19 04:21 PM Ryan Daniel J Co-President and RMD Dec 13 '23 Sale 118.07 10,000 1,180,700 166,308 Dec 15 04:43 PM Fukuzaki-Carlson Kristina EVP - Business Operations Dec 13 '23 Sale 117.03 2,500 292,575 30,070 Dec 15 04:40 PM Alsbrook Madeleine Thorp EVP - Talent Management Dec 04 '23 Sale 119.55 4,854 580,296 19,740 Dec 06 04:42 PM ALEXANDRIA REAL ESTATE EQUITIE 10% Owner Nov 03 '23 Sale 2.31 143,450 331,370 5,580,077 Nov 06 04:56 PM ALEXANDRIA REAL ESTATE EQUITIE 10% Owner Nov 02 '23 Sale 2.32 103,808 240,835 5,723,527 Nov 06 04:56 PM ALEXANDRIA REAL ESTATE EQUITIE 10% Owner Nov 01 '23 Sale 2.36 172,742 407,671 5,827,335 Nov 02 04:44 PM ALEXANDRIA REAL ESTATE EQUITIE 10% Owner Oct 31 '23 Sale 2.41 155,000 373,550 6,000,077 Nov 02 04:44 PM MARCUS JOEL S Executive Chairman May 08 '23 Sale 122.20 7,500 916,500 351,354 May 10 04:35 PM
Index RUT P/E - EPS (ttm) -1.46 Insider Own 2.67% Shs Outstand 104.33M Perf Week 1.23%
Market Cap 7.64B Forward P/E 70.88 EPS next Y 1.03 Insider Trans -19.62% Shs Float 101.54M Perf Month 5.08%
Income -139.67M PEG - EPS next Q -0.32 Inst Own 86.54% Short Float 3.54% Perf Quarter 8.74%
Sales 464.37M P/S 16.46 EPS this Y 56.45% Inst Trans 1.77% Short Ratio 3.72 Perf Half Y 51.36%
Book/sh 6.14 P/B 11.94 EPS next Y 262.57% ROA -18.84% Short Interest 3.59M Perf Year 20.02%
Cash/sh 4.79 P/C 15.30 EPS next 5Y - ROE -22.39% 52W Range 45.50 - 84.89 Perf YTD 2.29%
Dividend Est. - P/FCF - EPS past 5Y 12.47% ROI -23.10% 52W High -13.70% Beta 1.01
Dividend TTM - Quick Ratio 5.31 Sales past 5Y 7617.73% Gross Margin 92.73% 52W Low 61.01% ATR (14) 3.39
Dividend Ex-Date - Current Ratio 5.41 EPS Y/Y TTM 46.55% Oper. Margin -34.32% RSI (14) 55.36 Volatility 3.13% 4.10%
Employees 610 Debt/Eq 0.03 Sales Y/Y TTM 85.51% Profit Margin -30.08% Recom 1.38 Target Price 91.14
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q 36.12% Payout - Rel Volume 0.62 Prev Close 72.13
Sales Surprise -2.64% EPS Surprise 33.47% Sales Q/Q 50.34% Earnings Feb 22 BMO Avg Volume 964.43K Price 73.26
SMA20 4.36% SMA50 5.53% SMA200 17.72% Trades
Volume 594,740 Change 1.57%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-03-24 Initiated Robert W. Baird
Outperform
$83
Dec-11-23 Initiated TD Cowen
Outperform
$75
Apr-20-23 Initiated Morgan Stanley
Overweight
$80
Aug-22-22 Downgrade Goldman
Buy → Neutral
$64 → $49
Jul-07-22 Initiated Mizuho
Buy
$74
Jun-14-22 Initiated UBS
Buy
$75
Apr-22-22 Initiated Piper Sandler
Neutral
$59
Feb-16-22 Initiated Goldman
Buy
$64
Sep-23-21 Initiated Needham
Buy
$55
Dec-15-20 Initiated BofA Securities
Buy
$40
Dec-10-20 Initiated Goldman
Buy
$38
Feb-20-20 Initiated Evercore ISI
Outperform
Jan-31-20 Downgrade JP Morgan
Overweight → Neutral
$26
Dec-24-19 Reiterated Canaccord Genuity
Buy
$29 → $65
Aug-12-19 Initiated Jefferies
Buy
$16
Feb-26-18 Initiated JP Morgan
Overweight
Feb-08-18 Initiated RBC Capital Mkts
Outperform
$33
Dec-15-17 Initiated Canaccord Genuity
Buy
$31
Nov-08-17 Upgrade SunTrust
Hold → Buy
Sep-07-17 Upgrade Piper Jaffray
Neutral → Overweight
Show Previous Ratings
Apr-25-24 10:01AM
Apr-24-24 04:01PM
11:31AM
Apr-22-24 11:10AM
Apr-17-24 08:46PM
09:44AM
Loading…
09:44AM
(Investor's Business Daily)
09:21AM
07:36AM
Apr-16-24 04:06PM
04:00PM
(Investor's Business Daily)
12:19PM
09:08AM
(Investor's Business Daily)
07:14AM
07:00AM
Mar-19-24 08:30AM
01:16AM
Loading…
Mar-12-24 01:16AM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Feb-28-24 05:01AM
Feb-27-24 08:00AM
Feb-23-24 11:59AM
08:41AM
Feb-22-24 07:59AM
(Associated Press Finance)
07:53AM
07:30AM
Feb-15-24 10:00AM
Feb-13-24 11:51AM
(Investor's Business Daily)
Feb-10-24 03:07PM
(Investor's Business Daily)
Feb-08-24 08:00AM
Feb-05-24 11:11PM
09:01PM
Loading…
Jan-18-24 09:01PM
Jan-12-24 07:02PM
09:23AM
Jan-05-24 11:02AM
Jan-02-24 08:00AM
Jan-01-24 09:55AM
Dec-20-23 02:15PM
Dec-19-23 12:00PM
Dec-16-23 03:02PM
Dec-13-23 01:11PM
(Investor's Business Daily)
Dec-05-23 08:00AM
Nov-23-23 09:55AM
Nov-15-23 04:31PM
08:00AM
01:03AM
Nov-07-23 09:55AM
Nov-03-23 02:51PM
Nov-02-23 10:17AM
07:40AM
(Associated Press Finance)
07:30AM
Oct-31-23 08:00AM
Oct-29-23 07:00AM
Oct-26-23 10:02AM
08:00AM
Sep-20-23 08:00AM
05:05AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-04-23 08:40AM
08:00AM
Aug-03-23 08:55AM
07:53AM
07:30AM
Jul-28-23 08:00AM
Jun-20-23 02:13PM
(Investor's Business Daily)
Jun-09-23 11:30AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-29-23 07:26AM
May-08-23 10:04AM
09:19AM
May-04-23 08:50PM
08:45AM
07:47AM
07:30AM
May-02-23 10:01AM
08:00AM
Apr-27-23 10:03AM
Apr-26-23 08:00AM
Apr-21-23 11:28AM
Apr-20-23 01:40PM
(Investor's Business Daily)
Apr-17-23 06:40AM
Apr-11-23 08:00AM
Mar-31-23 11:30AM
Mar-29-23 04:40PM
11:24AM
08:12AM
05:36AM
Mar-28-23 04:20PM
(Investor's Business Daily) +16.40%
12:27PM
10:04AM
(Investor's Business Daily)
07:00AM
Mar-03-23 10:52AM
Mar-02-23 05:31AM
Mar-01-23 08:45AM
07:30AM
Feb-22-23 10:00AM
Feb-14-23 08:00AM
Feb-08-23 08:00AM
Jan-03-23 08:00AM
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mates Sharon Chairman and CEO Apr 24 '24 Option Exercise 17.26 20,020 345,618 1,070,329 Apr 25 05:08 PM RIGGS RORY B Director Mar 20 '24 Option Exercise 18.56 20,000 371,200 99,235 Mar 22 04:12 PM Mates Sharon Chairman, President & CEO Mar 11 '24 Sale 65.21 20,565 1,341,123 1,050,309 Mar 11 08:33 PM Hineline Lawrence J. SVP of Finance, CFO Mar 11 '24 Sale 65.96 10,121 667,587 0 Mar 11 08:33 PM Halstead Michael EVP and General Counsel Mar 11 '24 Sale 65.97 7,345 484,537 0 Mar 11 08:32 PM Neumann Mark EVP, Chief Commercial Officer Mar 11 '24 Sale 65.61 7,345 481,931 29,700 Mar 11 08:31 PM Durgam Suresh K. EVP, Chief Medical Officer Mar 11 '24 Sale 65.59 3,712 243,482 19,803 Mar 11 08:31 PM Hineline Lawrence J. SVP of Finance, CFO Mar 10 '24 Option Exercise 56.73 4,539 257,497 4,539 Mar 11 08:33 PM Mates Sharon Chairman, President & CEO Mar 07 '24 Sale 66.50 40,712 2,707,277 1,050,309 Mar 11 08:33 PM Hineline Lawrence J. SVP of Finance, CFO Mar 07 '24 Sale 66.60 13,132 874,560 0 Mar 11 08:33 PM Neumann Mark EVP, Chief Commercial Officer Mar 07 '24 Sale 66.57 13,132 874,179 29,700 Mar 11 08:31 PM Halstead Michael EVP and General Counsel Mar 07 '24 Sale 66.15 13,132 868,698 0 Mar 11 08:32 PM Durgam Suresh K. EVP, Chief Medical Officer Mar 07 '24 Sale 66.56 6,450 429,308 16,170 Mar 11 08:31 PM VAN NOSTRAND ROBERT L Director Feb 27 '24 Option Exercise 18.56 20,000 371,200 29,611 Feb 28 07:41 PM VAN NOSTRAND ROBERT L Director Feb 27 '24 Sale 72.93 20,000 1,458,650 9,611 Feb 28 07:41 PM MARCUS JOEL S Director Feb 26 '24 Option Exercise 48.93 36,757 1,798,678 65,990 Feb 27 07:57 PM Hineline Lawrence J. SVP of Finance, CFO Feb 26 '24 Option Exercise 36.89 5,882 216,987 5,882 Feb 27 08:00 PM MARCUS JOEL S Director Feb 26 '24 Sale 68.68 26,328 1,808,253 39,662 Feb 27 07:57 PM Mates Sharon Chairman, President & CEO Feb 26 '24 Sale 69.79 22,590 1,576,464 1,050,309 Feb 27 07:59 PM Hineline Lawrence J. SVP of Finance, CFO Feb 26 '24 Sale 69.43 13,337 925,961 0 Feb 27 08:00 PM Neumann Mark EVP, Chief Commercial Officer Feb 26 '24 Sale 70.13 7,907 554,491 29,700 Feb 27 07:58 PM Halstead Michael EVP and General Counsel Feb 26 '24 Sale 69.53 7,907 549,784 0 Feb 27 08:00 PM Durgam Suresh K. EVP, Chief Medical Officer Feb 26 '24 Sale 70.17 4,112 288,534 9,488 Feb 27 07:58 PM Mates Sharon Chairman, President & CEO Feb 02 '24 Sale 67.07 33,885 2,272,694 1,050,309 Feb 05 06:10 PM Neumann Mark EVP, Chief Commercial Officer Feb 02 '24 Sale 67.15 11,860 796,367 29,700 Feb 05 06:07 PM Halstead Michael EVP and General Counsel Feb 02 '24 Sale 66.42 11,860 787,719 0 Feb 05 06:13 PM Hineline Lawrence J. SVP of Finance, CFO Feb 02 '24 Sale 66.62 11,183 745,037 0 Feb 05 06:05 PM Durgam Suresh K. EVP, Chief Medical Officer Feb 02 '24 Sale 67.19 6,167 414,355 5,693 Feb 05 06:02 PM Mates Sharon Chairman, President & CEO Jan 18 '24 Option Exercise 16.86 67,917 1,145,081 1,118,226 Jan 18 07:47 PM Mates Sharon Chairman, President & CEO Jan 18 '24 Sale 65.19 67,917 4,427,848 1,050,309 Jan 18 07:47 PM Mates Sharon Chairman, President & CEO Jan 17 '24 Option Exercise 16.86 48,084 810,696 1,098,393 Jan 18 07:47 PM Mates Sharon Chairman, President & CEO Jan 17 '24 Sale 66.24 48,084 3,185,062 1,050,309 Jan 18 07:47 PM Mates Sharon Chairman, President & CEO Jan 16 '24 Option Exercise 16.86 75,361 1,270,586 1,125,670 Jan 18 07:47 PM Mates Sharon Chairman, President & CEO Jan 16 '24 Sale 67.25 75,361 5,067,982 1,050,309 Jan 18 07:47 PM Halstead Michael EVP and General Counsel Jan 11 '24 Option Exercise 13.60 50,000 680,051 50,000 Jan 12 06:02 PM Halstead Michael EVP and General Counsel Jan 11 '24 Sale 66.83 50,000 3,341,699 0 Jan 12 06:02 PM Durgam Suresh K. EVP, Chief Medical Officer Jan 02 '24 Option Exercise 19.87 62,282 1,237,543 62,282 Jan 04 07:54 PM Durgam Suresh K. EVP, Chief Medical Officer Jan 02 '24 Sale 70.60 62,282 4,397,113 0 Jan 04 07:54 PM Durgam Suresh K. EVP, Chief Medical Officer Dec 13 '23 Sale 65.00 21,262 1,382,030 0 Dec 15 05:01 PM Neumann Mark EVP, Chief Commercial Officer Nov 06 '23 Option Exercise 23.94 26,754 640,491 72,093 Nov 08 05:31 PM Neumann Mark EVP, Chief Commercial Officer Nov 06 '23 Sale 55.63 42,393 2,358,152 29,700 Nov 08 05:31 PM Mates Sharon Chairman, President & CEO Sep 19 '23 Sale 54.17 44,413 2,405,852 1,050,309 Sep 19 08:40 PM Mates Sharon Chairman, President & CEO Sep 18 '23 Sale 53.76 55,587 2,988,213 1,094,722 Sep 19 08:40 PM Neumann Mark EVP, Chief Commercial Officer Aug 07 '23 Option Exercise 18.59 55,300 1,028,027 100,639 Aug 09 06:05 PM Neumann Mark EVP, Chief Commercial Officer Aug 07 '23 Sale 58.79 55,300 3,251,087 45,339 Aug 09 06:05 PM Durgam Suresh K. EVP, Chief Medical Officer Jul 17 '23 Sale 65.00 1,842 119,730 21,262 Jul 20 05:47 PM Hineline Lawrence J. SVP of Finance CFO Jun 14 '23 Option Exercise 42.30 81,854 3,462,317 81,854 Jun 16 05:05 PM Hineline Lawrence J. SVP of Finance CFO Jun 14 '23 Sale 63.97 81,854 5,236,329 0 Jun 16 05:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
